Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

AHA Annual Statistics Show COVID’s Disruptive Impact

L.A. McKeown

January 30, 2023

News Daily News

Mediterranean Diet Bests Low Fat for Secondary Prevention: CORDIOPREV

Michael O'Riordan

May 09, 2022

News Daily News

Sleep Apnea Awareness, Treatment May Improve Some CVD Outcomes: AHA

L.A. McKeown

June 23, 2021

News Daily News

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

Shelley Wood

March 10, 2020

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Conference News ACC 2019

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Michael O'Riordan

March 20, 2019

News Conference News ISC 2019

Should Pioglitazone Be Used More for Secondary Stroke Prevention in Prediabetes?

Todd Neale

February 14, 2019

News Daily News

Even After Recent ACS, Diabetic Patients With Multivessel Disease Fare Better With CABG

L.A. McKeown

December 11, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Daily News

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

Shelley Wood

September 28, 2016

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Daily News

Vorapaxar Effective for Secondary Prevention in Diabetic Patients With Prior MI

L.A. McKeown

February 22, 2015

News Daily News

Vorapaxar es Eficaz como Prevención Secundaria en Pacientes Diabéticos con Antecedentes de IM

L.A. McKeown

February 22, 2015

News Daily News

Prasugrel Inhibits Platelet Function Better Than High-Dose Clopidogrel in Diabetics

Jason Kahn

January 26, 2011

Advertisement

AHA Annual Statistics Show COVID’s Disruptive Impact

Mediterranean Diet Bests Low Fat for Secondary Prevention: CORDIOPREV

Sleep Apnea Awareness, Treatment May Improve Some CVD Outcomes: AHA

LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Modest LDL Cholesterol Reduction With Bempedoic Acid in Among High-Risk Patients: CLEAR Wisdom

Should Pioglitazone Be Used More for Secondary Stroke Prevention in Prediabetes?

Even After Recent ACS, Diabetic Patients With Multivessel Disease Fare Better With CABG

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Chelation Encore: TACT2 Trial Gets Go-ahead for Controversial Post-MI Treatment in Diabetes

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

Vorapaxar Effective for Secondary Prevention in Diabetic Patients With Prior MI

Vorapaxar es Eficaz como Prevención Secundaria en Pacientes Diabéticos con Antecedentes de IM

Prasugrel Inhibits Platelet Function Better Than High-Dose Clopidogrel in Diabetics

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content